Idogen signs collaboration agreement for the production of cell therapy in haemophilia
Idogen AB (Spotlight Stock Market: IDOGEN) announced today that the company has signed a collaboration agreement for production with the Radboud University Medical Center in the Netherlands, a university that is a global leader in the field and has 20 years of experience manufacturing cell therapy. The agreement marks a significant step in adapting and upscaling the manufacturing of the company’s cell therapy products prior to the start of clinical trials.The collaboration aims to efficiently adapt Idogen’s technology platform for clinical use and to ensure appropriate manufacturing